Search Results

Science 37, a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets.

Science 37 Holdings, Inc., announced its selection as winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.

Science 37 Holdings, Inc. today announced the launch of a stand-alone Patient Recruitment Solution to deliver patients to sites that are eligible, medically reviewed, and fully consented.

Science 37 Holdings, Inc. announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.

Science 37 Holdings, Inc., a leader in enhancing patient access to clinical trials, announced the final enrollment figures from its 20-month engagement with a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders.

eMed, LLC (“eMed”) today announced that its wholly-owned subsidiary, Marlin Merger Sub Corporation, a Delaware corporation (“Purchaser”), has commenced a cash tender offer to purchase all the outstanding shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. (NASDAQ: SNCE) (“Science 37") for a price of $5.75 per share (the “Offer”).

Science 37 Holdings, Inc. disclosed the latest enrollment figures resulting from its Metasite™ and Patient Recruitment partnership with a leading biotech company whose asthma drug is currently undergoing a Phase 3 clinical trial.

Science 37 Holdings, Inc today announced that it has entered into a definitive merger agreement to be acquired by eMed, LLC (“eMed”), the leader in on-demand virtual care and treatment for consumers.

Oncternal Therapeutics will lay off about 10 workers as it explores “strategic alternatives” that could include asset sales or an M&A.

Science 37 Holdings, Inc. announced today that it will effect a 1-for-20 reverse stock split (“Reverse Stock Split”) of its outstanding common stock, par value $0.0001 per share (“Common Stock”), that will become effective on December 8, 2023, at 12:01 a.m., Eastern Time.